Download

Fragment-based drug design (FBDD) has emerged as a powerful strategy in drug discovery, particularly for identifying novel scaffolds and binding sites for challenging targets. We have employed a combination of Spectral Shift and TR-FRET technologies to discover new molecular glue scaffolds. Our fragment library is diverse and includes a rich variety of E3 ligases from different species, providing a sustainable and versatile screening platform.

Download

Induced proximity, which utilizes small molecules to facilitate an interaction between two proteins to harness natural biological pathways, represents a revolution in synthetic chemistry and drug discovery [1]. This area has gained significant clinical traction, with targeted protein degradation leading the way. One example is Molecular glue degraders (MGDs), which induce the proximity of target protein to E3 ubiquitin ligases, leading to target ubiquitination and degradation. The mechanism is different from traditional inhibitors in drug discovery and broaden the approach, especially for the target used to be considered "undruggable". MRT-6160, a first-in-class VAV1-directed MGDs currently in clinical phase I, showed the remarkable potential in Immunology and inflammatory diseases such as rheumatoid arthritis and colitis [2][3]. Current advancements highlight its ability to reduce proinflammatory cytokine production, inhibit pathogenic T cell polarization, and mitigate autoimmune responses.

Download

In the development of new drugs, it is crucial to know the safety profile of drug candidates in advance, as this can prevent the drug from being withdrawn from the market due to safety concerns after launch, thus reducing the risk for pharmaceutical companies.

It is estimated that approximately 75% of all adverse drug reactions (ADRs) are dose-dependent type A reactions, which can be predicted according to the pharmacological profiles of drug candidates. The pharmacological profiles are mainly divided into primary effects, which are related to the action of the compound at its intended target, and secondary effects, which arise from interactions with non-primary targets, i.e. off-target effects. Off-target interactions are often the cause of ADRs in animal models or clinical studies, so careful characterization and identification of the secondary pharmacological profiles of drug candidates early in the drug discovery process could help reduce the incidence of type A ADRs.

Download

High-throughput screening of a cancer cell panel represents a pivotal instrument in the armamentarium of drug discovery and development. The sensitivity profiles of these cell lines serve as a cornerstone for the refinement of in vivo model systems and for the stratification of patient cohorts in clinical trials. Werner Syndrome RecQ Helicase (WRN), a member of the RecQ helicase family, is instrumental in the preservation of genomic integrity. Its multifaceted role encompasses DNA repair, replication, recombination, and telomere maintenance. WRN has garnered significant attention as a potential therapeutic nexus in oncology, particularly within the context of tumors exhibiting microsatellite instability (MSI). The synthetic lethality between WRN and MSI has been the subject of intensive research, demonstrating that WRN inhibition is selectively toxic to cancer cells harboring a high microsatellite instability (MSI-H) phenotype, which is a characteristic observed across a spectrum of malignancies, including colorectal, endometrial, and gastric cancers.